Navigation Links
FDA Approves EDARBI (azilsartan medoxomil) for the Treatment of Hypertension
Date:2/25/2011

DEERFIELD, Ill. and OSAKA, Japan, Feb. 25, 2011 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., today announced that the U.S. Food and Drug Administration (FDA) approved EDARBI (azilsartan medoxomil) for the treatment of hypertension, or high blood pressure, in adults. EDARBI is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone that constricts blood vessels. When the angiotensin II receptor is blocked, blood vessels stay relaxed and open and blood pressure can be reduced. EDARBI is approved as a once-daily oral therapy for use alone and for use in combination with other antihypertensive medications.

Takeda Global Research & Development Center, Inc. U.S. submitted a new drug application (NDA) for EDARBI in April 2010. The NDA was supported by seven controlled phase 3 clinical trials involving more than 5,900 patients with hypertension. Pivotal phase 3 studies showed EDARBI (80 mg/day) was statistically superior to placebo and the highest approved doses of two commonly prescribed ARBs, olmesartan medoxomil (40 mg/day) and valsartan (320 mg/day), in lowering both clinic and 24-hour mean blood pressure measurements.

"We are pleased to be able to build upon our global expertise in the cardiovascular therapeutic area with the approval of EDARBI in the U.S.," said Shinji Honda, president and CEO, Takeda Pharmaceuticals North America. "Through the discovery, development and commercialization of new medicines, Takeda is committed to bringing therapies like EDARBI to market. EDARBI is an important new treatment option for patients with hypertension and the health care professionals who treat them."

The safety and efficacy of EDARBI were studied as a once-daily oral therapy, as well as in combination with chlorthalidone and amlodipine. Results from the phase 3 clinical trials sh
'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Approves Product to Prevent Bleeding in People With Rare Genetic Defect
2. FDA Approves First 3-D Mammography Imaging System
3. FDA Approves 1st Pacemaker Designed to Work Safely During Some MRI Exams
4. FDA Approves Hologics Makena™ (Formerly Referred to as Gestiva™) Pharmaceutical
5. FDA Approves Drug to Reduce Risk of Preterm Birth in At-Risk Pregnant Women
6. FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth
7. FDA Approves Viibryd to Treat Major Depressive Disorder
8. FDA Approves Head Lice Treatment for Children and Adults
9. FDA Approves Opioid Analgesic to Help Cancer Patients Manage Pain
10. VIDEO from Endo Pharmaceuticals Available on thenewsmarket.com: FDA Approves New Treatment for Low Testosterone
11. FDA Approves New Dosage Strength for INTELENCE®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... today announced it has established a relief fund ... that has gripped much of the nation. AARP and its ... support these emergency relief efforts AARP and AARP Foundation will ... to $500,000 in aid. The matching program will be administered ...
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. (OTC ... U.S. provisional patent application concerning composition of matter, biological ... targeted tumor cell death.  This patent ... double stranded RNA molecules (VSRNAs) which interfere with the ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... evaluates the efficacy of new device for detecting polyps that ... ... Oct. 7 At the American College of,Gastroenterology Annual Scientific ... presented results from a,multi-institutional clinical study that evaluated the efficacy ...
... Results of FLEXX Trial Presented at the Osteoarthritis ... Oct. 7 Ferring Pharmaceuticals Inc.,recently presented results ... showing that EUFLEXXA(R) (1% sodium hyaluronate), a highly ... acid,(IA-HA), is superior to intra-articular saline (IA-saline) for ...
Cached Medicine Technology:National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 2National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 3National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 4National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 5Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 2Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 3Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 4
(Date:7/9/2014)... There has been a sharp increase in the ... using MyChart, the online, interactive service that allows patients ... healthcare providers, schedule appointments, and renew prescriptions. , Over ... MyChart each year increased five-fold, while the ... 10-fold, according to a study by Dr. David ...
(Date:7/9/2014)... The National Institute of Allergy and Infectious Diseases ... has launched an early-stage clinical trial of CRS3123, ... Clostridium difficile ( C. difficile ) infection. ... agent that inhibits C. difficile growth while sparing ... will enroll up to 30 healthy men and ...
(Date:7/9/2014)... , , , , ... , , , AUDIO: ... and approximately 30cm from the bullet... , , Click here ... , , , , , ... , , , , , University of Southampton researchers, with assistance from the Ministry ...
(Date:7/8/2014)... The UCLA Program in Memory Restoration has been awarded ... Projects Agency (DARPA) for a four -year project aiming ... UCLA team of experts in neurosurgery, engineering, neurobiology, psychology ... test a memory prosthesis in the brain. , Memory ... of the brain encode information, store it and retrieve ...
(Date:7/8/2014)... have discovered a biomarker that could give expecting mothers ... reliably predict that a pregnant woman may develop preeclampsia, ... pregnancy. , Preeclampsia is a cardiovascular disorder generally occurring ... delivery, creating immediate and potentially lifelong risks to both ... protein in the urine, and is typically diagnosed in ...
Breaking Medicine News(10 mins):Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7Health News:DARPA awards UCLA $15 million to restore lost memory 2Health News:DARPA awards UCLA $15 million to restore lost memory 3Health News:UI researchers find early predictor for preeclampsia 2Health News:UI researchers find early predictor for preeclampsia 3
... 15 The Endovascular Forum, Inc. (EVF), an ... Cardiovascular Angiography,and Interventions (SCAI), announced a collaboration to ... complex clinical skills,development in Cardiovascular medicine. The partnership ... developing a new generation of tools for,physicians to ...
... reform should make improved quality and efficiency paramount and move ... as a shared national resource, DMAA: The Care Continuum Alliance ... "The time is now to change the current ... Health Care Reform." DMAA represents organizations and individuals dedicated to ...
... shows extent, impact of family caregiving in state. , ... to family members or loved ones need information on available resources ... home & community-based services be increased, according to a survey released ... are or have been caregivers. , , ...
... of the men who took part in the prostate cancer ... diagnosed with the disease and the majority of those were ... the December issue of the urology journal BJU International ... from 55 to 74 took part in the multi-centre Prostate, ...
... Achievements of Past Century Include Major Milestones in the Advancement ... , , ALEXANDRIA, Va., Dec. ... its Centennial Year: "Celebrating the Legacy, Forging the Future." ... story of one person who turned a personal struggle with ...
... Study Led by M.D. Anderson Cancer Center To Evaluate Surgery ... ... Fla. (PRWEB) December 15, 2008 -- CyberKnife Center of Palm Beach, ... enrolled in the landmark study comparing traditional surgery and CyberKnife® radiosurgery ...
Cached Medicine News:Health News:The Endovascular Forum, Inc. and the Society for Cardiovascular Angiography and Interventions Partner to Extend the Influence of Electronic Medical Care Innovation to Cardiovascular Medicine Through www.EndoVascular.Org, a Global, Multi-disciplinary Care 2Health News:The Endovascular Forum, Inc. and the Society for Cardiovascular Angiography and Interventions Partner to Extend the Influence of Electronic Medical Care Innovation to Cardiovascular Medicine Through www.EndoVascular.Org, a Global, Multi-disciplinary Care 3Health News:The Endovascular Forum, Inc. and the Society for Cardiovascular Angiography and Interventions Partner to Extend the Influence of Electronic Medical Care Innovation to Cardiovascular Medicine Through www.EndoVascular.Org, a Global, Multi-disciplinary Care 4Health News:DMAA Health Care Reform Principles Call for Focus on Quality, Efficiency 2Health News:DMAA Health Care Reform Principles Call for Focus on Quality, Efficiency 3Health News:Caregivers in Maryland Call for Increased Funding, Support 2Health News:USA's largest ever prostate cancer screening program shows high compliance and consistent results 2Health News:USA's largest ever prostate cancer screening program shows high compliance and consistent results 3Health News:Mental Health America Celebrates 100 Years of Mental Health Advocacy and Support 2Health News:Mental Health America Celebrates 100 Years of Mental Health Advocacy and Support 3Health News:First Patient from CyberKnife Center of Palm Beach Enrolled in Worldwide Landmark Study of Operable Lung Cancer Patients 2Health News:First Patient from CyberKnife Center of Palm Beach Enrolled in Worldwide Landmark Study of Operable Lung Cancer Patients 3
Enzyme Immunoassay of -Thromboglobulin Antigen by ELISA Method, 96 tests....
HbA1c / HbCalibrator...
Heparin-Platelet Factor 4 Induced Antibody...
Multi-constituent Calibration Plasma for Functional Assays of Coagulation Parameters on STA© Analyzers....
Medicine Products: